Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
Public ClinicalTrials.gov record NCT02378480. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Study identification
- NCT ID
- NCT02378480
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Enrollment
- 655 participants
Conditions and interventions
Interventions
- Linezolid Drug
- Omadacycline Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2015
- Primary completion
- Mar 31, 2016
- Completion
- Apr 30, 2016
- Last update posted
- Mar 20, 2019
2015 – 2016
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 261 | Mobile | Alabama | 36608 | — |
| Site 262 | Chula Vista | California | 91911 | — |
| Site 254 | La Mesa | California | 91942 | — |
| Site 258 | Oceanside | California | 92056 | — |
| Site 252 | Santa Ana | California | 92705 | — |
| Site 260 | Santa Ana | California | 92705 | — |
| Site 269 | Stockton | California | 95204 | — |
| Site 259 | Miami | Florida | 33144 | — |
| Site 264 | West Palm Beach | Florida | 33407 | — |
| Site 256 | Augusta | Georgia | 30909 | — |
| Site 253 | Columbus | Georgia | 31904 | — |
| Site 257 | Springfield | Massachusetts | 01199 | — |
| Site 268 | Detroit | Michigan | 48202 | — |
| Site 266 | Butte | Montana | 59701 | — |
| Site 263 | Las Vegas | Nevada | 89119 | — |
| Site 270 | Somers Point | New Jersey | 08244 | — |
| Site 273 | Buffalo | New York | 14215 | — |
| Site 255 | Rapid City | South Dakota | 57702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02378480, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2019 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02378480 live on ClinicalTrials.gov.